Mastodon

PanziCam (Tablets) Instructions for Use

Marketing Authorization Holder

Camellia SPC, LLC (Russia)

ATC Code

A09AA02 (Polyenzyme preparations (incl. lipase, protease))

Active Substance

Pancreatin (BAN)

Dosage Form

Bottle OTC Icon PanziCam Enteric-coated tablets: 10, 20, 30, 50, or 100 pcs.

Dosage Form, Packaging, and Composition

Enteric-coated tablets 1 tablet
Pancreatin
   With minimum enzymatic activity
Proteolytic
Lipolytic
Amylolytic
50 U
3000 U
3100 U

10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (10) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer bottles (1) – cardboard packs.
30 pcs. – polymer bottles (1) – cardboard packs.

Clinical-Pharmacological Group

Enzyme preparation

Pharmacotherapeutic Group

Digestive enzyme agent

Pharmacological Action

The enzymes included in the preparation facilitate the digestion of proteins, fats, and carbohydrates, which promotes their more complete absorption in the small intestine, improve the functional state of the gastrointestinal tract, and normalize digestive processes.

The maximum enzymatic activity is observed 30-45 minutes after taking the drug.

Indications

  • Replacement therapy for exocrine pancreatic insufficiency (in chronic inflammatory-dystrophic diseases, conditions after resection or irradiation);
  • Cystic fibrosis;
  • Flatulence, diarrhea of non-infectious origin;
  • To improve food digestion in individuals with normal gastrointestinal function in case of dietary errors (consumption of fatty foods, large amounts of food, irregular meals) and in cases of impaired chewing function, sedentary lifestyle, prolonged immobilization;
  • Preparation for X-ray examination and ultrasound of the abdominal organs.

ICD codes

ICD-10 code Indication
E84 Cystic fibrosis
K59.1 Functional diarrhea
K86.9 Unspecified disease of pancreas
K90.3 Pancreatic steatorrhea
K91.1 Postgastric surgery syndromes
K91.2 Postprocedural malabsorption, not elsewhere classified
K91.5 Postcholecystectomy syndrome
R14 Flatulence and related conditions (including abdominal bloating, belching)
Z51.4 Preparatory procedures for subsequent treatment or examination, not elsewhere classified
ICD-11 code Indication
CA25.Z Cystic fibrosis, unspecified
DA96.0Y Other specified intestinal malabsorption
DC14.1 Postcholecystectomy syndrome
DC35.2 Pancreatic steatorrhea
DC35.Z Other specified diseases of pancreas, unspecified
DC3Z Diseases of pancreas, unspecified
DD91.2 Functional diarrhea
DD93.Y Other specified functional gastrointestinal disorders in infants, toddlers and school-age children
DD9Z Functional gastrointestinal disorders, unspecified
DE11 Dumping syndrome
ME08 Flatulence and related conditions
QB9A Preparatory procedures for subsequent treatment

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Orally, during or after meals, swallowed whole with plenty of non-alkaline liquid (water, fruit juices).

The dose of the drug (calculated in terms of lipase) depends on age and the degree of pancreatic insufficiency.

The average dose for adults is 15,000 U/day; for complete exocrine pancreatic insufficiency – 400,000 U/day, which corresponds to the daily requirement of an adult for lipase.

The maximum daily dose is 15,000-20,000 U/kg.

In children over 3 years of age, the drug is used as prescribed by a doctor, 1-2 tablets during meals.

The duration of treatment can vary from several days (for digestive disorders due to dietary errors) to several months and even years (if constant replacement therapy is necessary).

Adverse Reactions

Rarely – diarrhea; with long-term use in high doses – hyperuricosuria, and in patients with cystic fibrosis – strictures in the ileocecal region and in the ascending colon.

Allergic reactions are possible.

Contraindications

  • Acute pancreatitis, exacerbation of chronic pancreatitis;
  • Galactose intolerance;
  • Lactase deficiency or glucose-galactose malabsorption syndrome;
  • Children under 3 years of age;
  • Hypersensitivity.

Use in Pregnancy and Lactation

The use of the drug during pregnancy and lactation (breastfeeding) is possible only if the expected positive effect for the mother outweighs the potential risk to the fetus or child.

Pediatric Use

Contraindicated in children under 3 years.

Overdose

Hyperuricosuria, hyperuricemia, in children – constipation.

Treatment: drug withdrawal, symptomatic therapy.

Drug Interactions

Reduces the absorption of iron preparations.

Storage Conditions

Store in a dry, light-protected place at a temperature not exceeding 25°C (77°F).

Keep out of reach of children.

Shelf Life

Shelf life – 2 years.

Dispensing Status

Over-the-counter.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS